Entera Bio (ENTX) EBT (2019 - 2026)

Entera Bio (ENTX) has reported EBT for 8 consecutive years, with -$3.6 million the latest figure, recorded in Q1 2026.

• Quarterly EBT fell 37.88% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (down 23.94% YoY) and the FY2025 annual result came in at -$11.4 million, down 20.07% from the prior year.
• EBT declined to -$3.6 million in Q1 2026 per ENTX's latest filing, from -$3.1 million in the prior quarter.
• Over the last five years, EBT for ENTX reached as high as -$2.0 million in Q4 2023 and fell as low as -$3.8 million in Q1 2022.
• A 5-year average of -$2.8 million and a median of -$2.7 million in 2025 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT tumbled 64.11% — and 2023, when it surged 42.23%.
• Year by year, EBT stood at -$3.1 million in 2022, then jumped by 35.25% to -$2.0 million in 2023, then dropped by 17.49% to -$2.3 million in 2024, then plunged by 33.87% to -$3.1 million in 2025, then decreased by 15.07% to -$3.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$3.6 million, -$3.1 million, and -$3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.